The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial

Abstract Background According to the World Health Organization, cardiovascular diseases (CVDs) are the leading non-communicable cause of death. Awareness of the individual risk profile is crucial to implement a healthy lifestyle and prevent CVDs. Multiple studies demonstrated that atherosclerosis, t...

Full description

Bibliographic Details
Main Authors: Benoît Bernar, Nina Gande, Katharina A. Stock, Anna Staudt, Raimund Pechlaner, Ralf Geiger, Andrea Griesmacher, Stefan Kiechl, Michael Knoflach, Ursula Kiechl-Kohlendorfer, for the Early Vascular Aging (EVA) Study Group
Format: Article
Language:English
Published: BMC 2020-02-01
Series:BMC Cardiovascular Disorders
Online Access:https://doi.org/10.1186/s12872-020-01357-9
id doaj-f2941af2825f4e67a3e2d8e50fd42173
record_format Article
spelling doaj-f2941af2825f4e67a3e2d8e50fd421732021-02-07T12:26:03ZengBMCBMC Cardiovascular Disorders1471-22612020-02-0120111010.1186/s12872-020-01357-9The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trialBenoît Bernar0Nina Gande1Katharina A. Stock2Anna Staudt3Raimund Pechlaner4Ralf Geiger5Andrea Griesmacher6Stefan Kiechl7Michael Knoflach8Ursula Kiechl-Kohlendorfer9for the Early Vascular Aging (EVA) Study GroupDepartment of Neurology, Medical University of InnsbruckDepartment of Pediatrics II, Medical University of InnsbruckDepartment of Pediatrics II, Medical University of InnsbruckDepartment of Pediatrics II, Medical University of InnsbruckDepartment of Neurology, Medical University of InnsbruckDepartment of Pediatrics III, Medical University of InnsbruckCentral Institute of Clinical Chemistry and Laboratory Medicine (ZIMCL), Medical University of InnsbruckDepartment of Neurology, Medical University of InnsbruckDepartment of Neurology, Medical University of InnsbruckDepartment of Pediatrics II, Medical University of InnsbruckAbstract Background According to the World Health Organization, cardiovascular diseases (CVDs) are the leading non-communicable cause of death. Awareness of the individual risk profile is crucial to implement a healthy lifestyle and prevent CVDs. Multiple studies demonstrated that atherosclerosis, the main cause of CVDs, begins early in life. Therefore, it may be necessary to start prevention programs already in childhood. Methods The EVA-Tyrol study is a population-based non-randomized controlled trial that will prospectively enroll 2000 participants from high schools and training companies in North- and East-Tyrol (Austria) and South-Tyrol (Italy). Participants will be assigned to either an intervention (n = 1500) or a control (n = 500) group. Intervention group participants will be enrolled at the 10th school grade (mean age 15–16 years), undergo two examinations within a two-year interval, with follow-up at the 12th grade (mean ages 17–18 years). Control group participants will be enrolled at the 12th grade (mean age 17–18 years). Medical examination will include anthropometric measurements, comprehensive lifestyle and dietary questionnaires, a fasting blood sample, high-resolution ultrasound of the carotid arteries, and measurement of carotid-femoral pulse wave velocity. Active intervention will consist of (1) enhancing knowledge about CVDs, (2) individual medical counseling based on the results of the baseline examination, (3) an online health promotion tool and (4) involvement of participants in planning and implementation of health promotion projects. Effectiveness of the intervention will be assessed by comparing the proportion subjects with ideal health metrics as defined by the American Heart Association between study groups. Discussion This study aims to improve cardiovascular health in Tyrolean adolescents by demonstrating the efficacy of a multi-layer health promotion program and may yield novel insights into the prevalence of vascular risk conditions and mechanisms of early vascular pathologies in adolescents. Trial registration EVA-Tyrol has been retrospectively registered at clinicaltrials.gov under NCT03929692 since April 29, 2019.https://doi.org/10.1186/s12872-020-01357-9
collection DOAJ
language English
format Article
sources DOAJ
author Benoît Bernar
Nina Gande
Katharina A. Stock
Anna Staudt
Raimund Pechlaner
Ralf Geiger
Andrea Griesmacher
Stefan Kiechl
Michael Knoflach
Ursula Kiechl-Kohlendorfer
for the Early Vascular Aging (EVA) Study Group
spellingShingle Benoît Bernar
Nina Gande
Katharina A. Stock
Anna Staudt
Raimund Pechlaner
Ralf Geiger
Andrea Griesmacher
Stefan Kiechl
Michael Knoflach
Ursula Kiechl-Kohlendorfer
for the Early Vascular Aging (EVA) Study Group
The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial
BMC Cardiovascular Disorders
author_facet Benoît Bernar
Nina Gande
Katharina A. Stock
Anna Staudt
Raimund Pechlaner
Ralf Geiger
Andrea Griesmacher
Stefan Kiechl
Michael Knoflach
Ursula Kiechl-Kohlendorfer
for the Early Vascular Aging (EVA) Study Group
author_sort Benoît Bernar
title The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial
title_short The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial
title_full The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial
title_fullStr The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial
title_full_unstemmed The Tyrolean early vascular ageing-study (EVA-Tyrol): study protocol for a non-randomized controlled trial
title_sort tyrolean early vascular ageing-study (eva-tyrol): study protocol for a non-randomized controlled trial
publisher BMC
series BMC Cardiovascular Disorders
issn 1471-2261
publishDate 2020-02-01
description Abstract Background According to the World Health Organization, cardiovascular diseases (CVDs) are the leading non-communicable cause of death. Awareness of the individual risk profile is crucial to implement a healthy lifestyle and prevent CVDs. Multiple studies demonstrated that atherosclerosis, the main cause of CVDs, begins early in life. Therefore, it may be necessary to start prevention programs already in childhood. Methods The EVA-Tyrol study is a population-based non-randomized controlled trial that will prospectively enroll 2000 participants from high schools and training companies in North- and East-Tyrol (Austria) and South-Tyrol (Italy). Participants will be assigned to either an intervention (n = 1500) or a control (n = 500) group. Intervention group participants will be enrolled at the 10th school grade (mean age 15–16 years), undergo two examinations within a two-year interval, with follow-up at the 12th grade (mean ages 17–18 years). Control group participants will be enrolled at the 12th grade (mean age 17–18 years). Medical examination will include anthropometric measurements, comprehensive lifestyle and dietary questionnaires, a fasting blood sample, high-resolution ultrasound of the carotid arteries, and measurement of carotid-femoral pulse wave velocity. Active intervention will consist of (1) enhancing knowledge about CVDs, (2) individual medical counseling based on the results of the baseline examination, (3) an online health promotion tool and (4) involvement of participants in planning and implementation of health promotion projects. Effectiveness of the intervention will be assessed by comparing the proportion subjects with ideal health metrics as defined by the American Heart Association between study groups. Discussion This study aims to improve cardiovascular health in Tyrolean adolescents by demonstrating the efficacy of a multi-layer health promotion program and may yield novel insights into the prevalence of vascular risk conditions and mechanisms of early vascular pathologies in adolescents. Trial registration EVA-Tyrol has been retrospectively registered at clinicaltrials.gov under NCT03929692 since April 29, 2019.
url https://doi.org/10.1186/s12872-020-01357-9
work_keys_str_mv AT benoitbernar thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT ninagande thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT katharinaastock thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT annastaudt thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT raimundpechlaner thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT ralfgeiger thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT andreagriesmacher thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT stefankiechl thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT michaelknoflach thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT ursulakiechlkohlendorfer thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT fortheearlyvascularagingevastudygroup thetyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT benoitbernar tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT ninagande tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT katharinaastock tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT annastaudt tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT raimundpechlaner tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT ralfgeiger tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT andreagriesmacher tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT stefankiechl tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT michaelknoflach tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT ursulakiechlkohlendorfer tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
AT fortheearlyvascularagingevastudygroup tyroleanearlyvascularageingstudyevatyrolstudyprotocolforanonrandomizedcontrolledtrial
_version_ 1724281169841750016